
Microplastics found in human semen, follicular fluid
Water availability
Corporate newsFacebookTweetLink
Follow
Scientists have detected microplastics — the tiny and pervasive fragments now found in our seas, drinking water, food and, increasingly, living tissue — in human semen and follicular fluid, according to new research.
A small group of 25 women and 18 men participated in the research, published Tuesday in the journal Human Reproduction. Microplastics were detected in 69% of the follicular fluid samples and 55% of the seminal fluid samples. Follicular fluid is the liquid that surrounds an egg in an ovarian follicle.
The research is an abstract — a short summary of completed research — and has not yet been peer reviewed. It was presented Tuesday in Paris at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology.
'Previous studies had already suggested this possibility, so the presence of microplastics in the human reproductive system is not entirely unexpected,' said lead research author Dr. Emilio Gómez-Sánchez, director of the assisted reproduction laboratory at Next Fertility Murcia in Spain, in a statement provided to the press. 'What did surprise us, however, is how widespread it is. This is not an isolated finding — it appears to be quite common.'
Microplastics are polymer fragments that range in size from less than 0.2 inches (5 millimeters) to 1/25,000th of an inch (1 micrometer). Polymers are chemical compounds with long chains of large and repetitive molecular units called monomers, and are known for being flexible and durable. Most plastics are synthetic polymers.
Plastics smaller than the measurement criteria for microplastics are considered nanoplastics, which are measured in billionths of a meter.
'Microplastics primarily enter the body through three routes: ingestion, inhalation, and skin contact,' Gómez-Sánchez said. 'From there, they can enter the bloodstream, which then distributes them throughout the body, including to the reproductive organs.'
In previous studies, the fragments have also been detected in various body parts or fluids including the lungs, placenta, brain, testicles, nose tissue at the base of the brain, penises and human stool.
'Decades of studies and the (US Food and Drug Administration) agree that microplastics are not a threat because exposure is extremely low and they are non-toxic,' said Dr. Chris DeArmitt, founder of the Plastics Research Council, via email.
However, while there is little to nothing known about the potential effects of microplastics on human health, chemicals used in plastic production — that often leach from plastics — are linked with health risks including hormonal disruptions, certain cancers, respiratory diseases and skin irritation.
The research participants were patients and donors at Next Fertility Murcia. The women were undergoing egg retrieval, formally known as follicular aspiration, for assisted reproduction, while the men were undergoing semen analysis. The authors stored and froze the samples in glass, then incubated them for two days before analyzing them using an imaging technique combining microscopy and infrared laser.
The research team also analyzed the containers used to collect and store samples to ensure they hadn't been contaminated with microplastics. The abstract doesn't disclose what materials the collection containers were made of.
Imaging revealed nine types of microplastics in the reproductive fluids. Over 50% of the follicular fluid samples contained polyamide (PA), polyurethane (PU) and polyethylene (PE), while polytetrafluoroethylene (PTFE) and polyethylene terephthalate (PET) were discovered in over 30% of the follicular fluid samples.
Polypropylene (PP), polyvinyl chloride (PVC) and polylactic acid (PLA) appeared in over 20% of the follicular fluid samples.
In the semen samples, 56% contained PTFE.
Synthetic polyamide is commonly known as nylon, often used in textiles, plastics and automotive parts. Polyurethane is commonly used in coatings, foams and adhesives for furniture, construction, automotive parts, footwear and more. Polyethylene and polypropylene are often found in packaging, construction uses and consumer goods, such as toys and kitchenware.
The plastic PTFE is widely used in nonstick cookware, while PET is found in many food and beverage containers. Polyvinyl chloride is often used in the construction, packaging and medical industries, while PLA is primarily found in food packing, medical implants and 3D-printed objects.
In most samples, the researchers found only one or two particles, but they detected up to five in others, Gómez-Sánchez said. Microplastic concentrations were higher in follicular fluid than in semen. However, the overall concentrations of microplastics in both fluids were relatively low when compared with the concentrations of non-plastic particles. The abstract didn't disclose what those non-plastic particles were.
'Sadly, (the findings) are not surprising,' said Dr. Matthew J. Campen — a researcher who helped lead the discoveries of microplastics in the brain and testicles — via email.
Though the research is preliminary, it does 'set the stage for more advanced studies of the relationship between plastics exposure and reproductive fitness,' added Campen, who wasn't involved in the study and is a regents' professor of pharmaceutical sciences at the University of New Mexico.
The research affirmed previous studies that had found microplastics in these reproductive fluids, and yet again raises important questions, including how these microplastics are absorbed in the intestine then transported to the gonads, Campen said.
'This suggests a very natural mechanism is being hijacked,' he added. 'It would also be important to assess plastics in the nanoscale range.'
People trying to conceive naturally or via in vitro fertilization may not need to be concerned about the findings, as they are only preliminary for now, Gómez-Sánchez said.
'We don't know if they have a direct effect on the capacity of a couple to conceive and carry a baby to term,' he added. 'Reproduction is a complex equation, and microplastics are a variable in this equation.'
The findings also can't yet be linked to more general health outcomes, experts said.
'So far, the effects of microplastics on humans have been mainly extrapolated from animal studies, where microplastics were administered at high concentrations,' Gómez-Sánchez said. 'We currently lack direct evidence regarding their impact on humans.'
Betsy Bowers, executive director of the EPS Industry Alliance, echoed these disclaimers and noted that the animal research results aren't indicative of harm at regular exposure levels. The EPS (expanded polystyrene) Industry Alliance is a North American trade association representing the EPS industry.
The finding that follicular fluid contained more microplastics than semen may be circumstantial, Gómez-Sánchez added, because the study group was small. However, when an ovary is stimulated for assisted reproduction, blood flow to the ovary increases, which may deliver more microplastics to the ovary, he explained.
Additional research is needed to identify the types and quantities of microplastics that could cause health problems, said Dr. Ranjith Ramasamy, a consultant urologist at Jumeirah American Clinic in Dubai. Ramasamy, who wasn't involved in the study, led the research that found microplastics in penises.
'The plan is to increase the number of cases and conduct a survey on lifestyle habits in order to determine if any of these habits are linked to higher concentrations of plastics found in the ovaries and seminal plasma,' Gómez-Sánchez said.
Gómez-Sánchez and the other researchers also plan to explore whether the presence of microplastics in reproductive fluids affects the quality of sperm and oocytes, he said. Oocytes are cells in ovaries that form an ovum, a mature female reproductive cell that can divide to create an embryo upon fertilization by sperm.
The significance of the findings isn't yet clear, but they should be considered an additional argument in favor of avoiding the use of plastics in our daily lives, said Dr. Carlos Calhaz-Jorge, professor of obstetrics and gynecology at the University of Lisbon in Portugal, in a news release. Calhaz-Jorge wasn't involved in the research.
Given the ubiquity of plastics, avoidance can be challenging, said Dr. Philip Landrigan, a pediatrician and director of the Program for Global Public Health and the Common Good at Boston College, via email. In addition to reducing obvious uses of plastic, you can also avoid using plastic cutting boards and eating ultraprocessed foods.
Also limit drinking water from plastic bottles, microwaving food in plastic containers and consuming hot food from plastic containers, Ramasamy said.
Food can be stored in glass, stainless steel or bamboo instead of plastic.
But 'the conversation needs to shift — immediately — to policymakers,' Campen said. 'Hoping that individual choices can make a difference has been clearly a losing strategy. Federal governments around the world need to make major changes to waste management and recycling policies.'
Annual plastic production by weight has increased by 250 times in the past 75 years and is on track to triple again by 2060, Landrigan said.
'To reduce plastic pollution and safeguard human health, it will be essential that the Global Plastics Treaty that is currently in negotiation at the United Nations impose a global cap on plastic production,' Landrigan, who wasn't involved in the research, added.
'But smart governments can act now,' Campen urged.
Sign up for CNN's Life, But Greener newsletter. Our limited newsletter series guides you on how to minimize your personal role in the climate crisis — and reduce your eco-anxiety.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Times
2 hours ago
- New York Times
454 Hints That a Chatbot Wrote Part of a Biomedical Researcher's Paper
Scientists know it is happening, even if they don't do it themselves. Some of their peers are using chatbots, like ChatGPT, to write all or part of their papers. In a paper published Wednesday in the journal Science Advances, Dmitry Kobak of the University of Tübingen and his colleagues report that they found a way to track how often researchers are using artificial intelligence chatbots to write the abstracts of their papers. The A.I. tools, they say, tend to use certain words — like 'delves,' 'crucial,' 'potential,' 'significant' and 'important' — far more often than human authors do. The group analyzed word use in the abstracts of more than 15 million biomedical abstracts published between 2010 and 2024, enabling them to spot the rising frequency of certain words in abstracts. The findings tap into a debate in the sciences over when it is and is not appropriate to use A.I. helpers for writing papers. When ChatGPT was introduced in November 2022, a collection of words started showing up with unusual frequency. Those words, the investigators report, were not used so often before the release of ChatGPT. They infer that the change in word usage is a telltale sign of A.I. In 2024, there were a total of 454 words used excessively by chatbots, the researchers report. Based on the frequency of the A.I.-favored words, Dr. Kobak and his team calculate that at least 13.5 percent of all biomedical abstracts appeared to have been written with the help of chatbots. And as many as 40 percent of abstracts by authors from some countries writing in a few less selective journals were A.I.-generated. Want all of The Times? Subscribe.


Forbes
3 hours ago
- Forbes
A Mysterious Interstellar Object Just Appeared — How To See It
Astronomers have discovered what they think may be an interstellar object passing through the solar system. At twice as wide as Mount Everest is tall, A11pl3Z would be the third interstellar object — an object that originates from outside the solar system — ever to be found, after 'Oumuamua in 2017 and a comet called 2I/Borisov in 2019. Telescopes around the world are now scrambling to observe it — including a virtual telescope that plans to share real-time images online. A11pl3Z could be similar to Oumuamua, the first confirmed interstellar object observed passing ... More through our solar system in 2017. (Artist's impression) getty Thought to be around 12 miles (20 kilometers) in diameter, A11pl3Z's eccentric trajectory suggests that it's from outside the solar system. 'Astronomers may have just discovered the third interstellar object passing through the Solar System!' wrote the European Space Agency Operations on X (Twitter). 'ESA's Planetary Defenders are observing the object, provisionally known as A11pl3Z, right now using telescopes around the world.' A11pl3Z was added to a list of Near-Earth Objects on July 1 by the International Astronomical Union's Minor Planet Center. It's thought to be a large asteroid or a comet, but more observations will be needed to confirm. At magnitude 18.8, A11pl3Z is far too dim to see with the naked eye or even with backyard telescopes. However, the Virtual Telescope Project will host an online observation on YouTube of A11pl3Z at 6:00 p.m. EDT on July 3, 2025. A11pl3Z poses no danger to Earth, but it will pass relatively close to Mars. It will reach its perihelion — the closest it will get to the sun — in October but will only get about as half as close to the sun as Earth is. According to EarthSky, at perihelion, it will be traveling at around 42 miles (68 kilometers) per second/second or about 152,000 miles (245,000 kilometers) per hour. Not only will it not get near Earth, but during its perihelion, it will be difficult for astronomers to study because it will be lost in the sun's glare as seen from Earth. After October, A11pl3Z will travel out of the solar system. If A11pl3Z is an interstellar object, it joins a very select group. The first known interstellar object ever identified was 'Oumuamua (also known as 1I/2017 U1) on Oct. 19, 2017, by the Pan-STARRS1 Near-Earth Object survey. Challenging astronomers' assumptions about how small bodies from another star system would look, 'Oumuamua — meaning 'a messenger from afar arriving first' in Hawaiian, according to NASA — displayed some strange behavior, moving too quickly to be an asteroid (and even accelerating) and leaving no trail of debris behind it, as comets do. It also varied in brightness, probably because it was sausage-shaped and spinning. All of this led some to speculate that 'Oumuamua was, in fact, an artificial creation of an advanced civilization. It wasn't — but since it was only discovered on its way out of the solar system, it was faint and frustrating for observers — which prompted plans for a 22-year mission to visit it. A 'rogue' Comet Arrives A second interstellar interloper, 2I/Borisov, was discovered in Crimea on Aug. 30, 2019, by Gennady Borisov, an amateur astronomer. It was way more impressive. While 'Oumuamua was estimated to have a diameter of 0.19 miles (0.3 kilometers), Borisov's was 3.7 miles (6 kilometers). It looked and behaved like a regular comet but with a very eccentric path that underlined its interstellar origin. As telescopes and sky surveys continue to improve, more interstellar objects will be discovered. About seven objects like 'Oumuamua should pass within one Earth-sun distance of the sun each year, according to a paper published in 2021 using data from the Gaia satellite. However, it calculated that interstellar comets like 2I/Borisov could occur once every decade. It went further, predicting that three objects per century could come from other galaxies. Further Reading Forbes Giant Glowing Object Found Close To Solar System — What To Know By Jamie Carter Forbes Second 'Nova' Explodes In Night Sky In Extremely Rare Event By Jamie Carter Forbes Bootid Meteor Shower: How To See 'Shooting Stars' By Jamie Carter
Yahoo
3 hours ago
- Yahoo
mAbxience Announces European Commission Approval of Denosumab Biosimilars
MADRID, July 2, 2025 /PRNewswire/ -- mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the European Commission has granted approval for its denosumab biosimilars Denbrayce® and Izamby®. This approval follows a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) and represents a major milestone in mAbxience's mission to provide high-quality, accessible, and affordable therapies worldwide. Denbrayce®, referencing Amgen's Xgeva®, is indicated for the prevention of skeletal-related events in adults with advanced malignancies involving bone, as well as for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone. Izamby®, referencing Amgen's Prolia®, is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, a condition that causes bones to become weak and more prone to breaking. "This approval is a testament to mAbxience's dedication to scientific excellence and our commitment to broadening access to essential biologic therapies," said Jurgen Van Broeck, CEO of mAbxience. "We are proud to contribute to reducing the burden of osteoporosis, cancer-related bone conditions, and rare bone diseases in Europe. This milestone brings us one step closer to ensuring that more patients across Europe can benefit from high-quality, affordable treatment options." Denosumab is a human monoclonal antibody that works by inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL), thereby preventing the development of osteoclasts, the cells responsible for bone breakdown. It is a well-established treatment for osteoporosis, treatment-induced bone loss, bone metastases, and giant cell tumor of bone. With the approval of these biosimilars mAbxience further demonstrates its expertise in the development and production of biosimilars, reinforcing its contribution to improving patient access to life-changing therapies and supporting the sustainability of healthcare systems across Europe. This approval marks another important step in mAbxience's mission to provide affordable, accessible and life-changing therapies worldwide. With a robust pipeline and a growing network of partners, mAbxience continues to enhance patient access to advanced treatments while supporting healthcare systems in managing the rising costs of biologic medicines. About mAbxience mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website ( or connect with us on LinkedIn. Photo: View original content to download multimedia: SOURCE mAbxience Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data